{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-26-001437","form_type":"8-K","ticker":"LEXX","cik":"0001348362","company_name":"Lexaria Bioscience Corp.","filed_at":"2026-09-01T13:16:32+00:00","discovered_at":"2026-09-01T13:17:31.335929+00:00","generated_at":"2026-09-01T13:17:36.792852+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lexaria receives AUD$3.67M Australian R&D tax credit for GLP-1 clinical study","bullets":["Received AUD$3,666,611.98 (USD$2.6M) R&D tax credit from Australian Tax Office on Aug 28, 2026.","Credit relates to clinical study GLP-1-H24-4 conducted by Lexaria (AU) Pty Ltd, wholly-owned subsidiary.","Funds deposited in Australian bank account to pursue additional R&D opportunities in Australia.","Subsidiary holds exclusive DehydraTECH rights for pharmaceutical GLP-1/GIP and CBD drugs in Australia."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-26-001437","json":"https://secwatch.observer/filing/0001640334-26-001437.json","markdown":"https://secwatch.observer/filing/0001640334-26-001437.md","text":"https://secwatch.observer/filing/0001640334-26-001437.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348362/000164033426001437/0001640334-26-001437-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348362/000164033426001437/lxrp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-01T13:17:36.792852+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}